FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 303:183-188 July 24, 1980 Number 4 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Symptomatic pulmonary disease occurred in 20 per cent of 93 patients with anaplastic gliomas being treated with carmustine (BCNU). An analysis of the variables has revealed a relation between the occurrence of pulmonary toxicity on the one hand, and the total cumulative dose of BCNU, the number of cycles over which the BCNU was administered, the history of lung disease, the patient's age, and the platelet-count nadir after the first course of BCNU on the other. An equation has been generated that allows prediction of pulmonary toxicity during the course of therapy with BCNU with 80 per cent accuracy. Pretreatment analysis of individual cases should allow safe use of BCNU and prevention of most of the serious pulmonary complications caused by this drug.

This article has been cited by other articles:

• LILES, A., BLATT, J., MORRIS, D., WARDROP, R. III, SHARMA, A., SZNEWAJS, A., GOLDSBY, R. (2008). Monitoring pulmonary complications in long-term childhood cancer survivors: Guidelines for the primary care physician. Cleveland Clinic Journal of Medicine 75: 531-539 [Abstract] [Full Text]  
• Oeffinger, K. C., Hudson, M. M. (2004). Long-term Complications Following Childhood and Adolescent Cancer: Foundations for Providing Risk-based Health Care for Survivors. CA Cancer J Clin 54: 208-236 [Abstract] [Full Text]  
• Reardon, D. A., Quinn, J. A., Rich, J. N., Gururangan, S., Vredenburgh, J., Sampson, J. H., Provenzale, J. M., Walker, A., Badruddoja, M., Tourt-Uhlig, S., Herndon, J. E. II, Dowell, J. M., Affronti, M. L., Jackson, S., Allen, D., Ziegler, K., Silverman, S., Bohlin, C., Friedman, A. H., Bigner, D. D., Friedman, H. S. (2004). Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro Oncol 6: 134-144 [Abstract]  
• Abushamaa, A. M., Sporn, T. A., Folz, R. J. (2002). Oxidative stress and inflammation contribute to lung toxicity after a common breast cancer chemotherapy regimen. Am. J. Physiol. Lung Cell. Mol. Physiol. 283: L336-L345 [Abstract] [Full Text]  
• Camus, Ph., Foucher, P., Bonniaud, Ph., Ask, K. (2001). Drug-induced infiltrative lung disease. Eur Respir J 18: 93S-100s [Abstract] [Full Text]  
• Rossi, S. E., Erasmus, J. J., McAdams, H. P., Sporn, T. A., Goodman, P. C. (2000). Pulmonary Drug Toxicity: Radiologic and Pathologic Manifestations. RadioGraphics 20: 1245-1259 [Abstract] [Full Text]  
• Folz, R. J., Elkordy, M. A. (1999). Coronavirus Pneumonia Following Autologous Bone Marrow Transplantation for Breast Cancer. Chest 115: 901-905 [Abstract] [Full Text]  
• Elias, A. D., Mark, E. J. (1997). Case 25-1997- A 60-Year-Old Man with Pulmonary Infiltrates after a Bone Marrow Transplantation. NEJM 337: 480-489 [Full Text]  
• WILCZYNSKI, S. W., ERASMUS, J. J., PETROS, W. P., VREDENBURGH, J. J., FOLZ, R. J. (1997). Delayed Pulmonary Toxicity Syndrome following High-dose Chemotherapy and Bone Marrow Transplantation for Breast Cancer. Am. J. Respir. Crit. Care Med. 157: 565-573 [Abstract] [Full Text]  
• Klein, R. C., Paddison, R. M. (1981). Failure of Corticosteroids to Prevent Carmustine-Induced Pulmonary Fibrosis in a Woman With Astrocytoma. Arch Neurol 38: 392-393 [Abstract]